Scientists test if common drug alters cancer treatment
NCT ID NCT05072106
Summary
This study aimed to understand how a drug for lung conditions (bosentan) affects the levels of a cancer drug (lurbinectedin) in the body. It involved 11 patients with advanced solid tumors who had run out of standard treatment options. Patients received the cancer drug both alone and combined with the lung drug in a specific order to measure the difference.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fundación Jiménez Diaz
Madrid, 28040, Spain
-
Hospital de Sanchinarro
Madrid, 28050, Spain
Conditions
Explore the condition pages connected to this study.